{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:53:01Z","timestamp":1789638781028,"version":"4.0.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T00:00:00Z","timestamp":1517961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.vaccine.2018.02.029","type":"journal-article","created":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T17:36:34Z","timestamp":1518888994000},"page":"1537-1541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials"],"prefix":"10.1016","volume":"36","author":[{"given":"Martina","family":"Kovac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himal","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony L.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron J.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Campora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Volpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Heineman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vaccine.2018.02.029_b0005","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: herpes zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.vaccine.2018.02.029_b0010","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMcp1403062","article-title":"Clinical practice Postherpetic neuralgia","volume":"371","author":"Johnson","year":"2014","journal-title":"N Engl J Med"},{"issue":"3 Suppl","key":"10.1016\/j.vaccine.2018.02.029_b0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1586\/erv.10.30","article-title":"Herpes zoster and postherpetic neuralgia","volume":"9","author":"Johnson","year":"2010","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2018.02.029_b0020","doi-asserted-by":"crossref","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","article-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective","volume":"4","author":"Kawai","year":"2014","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.vaccine.2018.02.029_b0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.mayocp.2015.09.015","article-title":"Risk of Stroke and myocardial infarction after herpes zoster in older adults in a US community population","volume":"91","author":"Yawn","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2018.02.029_b0030","first-page":"35","article-title":"Severe complications of herpes zoster","volume":"14","author":"Volpi","year":"2007","journal-title":"Herpes"},{"issue":"1","key":"10.1016\/j.vaccine.2018.02.029_b0035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.amjmed.2016.08.039","article-title":"Herpes zoster ophthalmicus: a review for the internist","volume":"130","author":"Vrcek","year":"2017","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2018.02.029_b0040","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.mayocp.2013.03.014","article-title":"Herpes zoster eye complications: rates and trends","volume":"88","author":"Yawn","year":"2013","journal-title":"Mayo Clin Proc"},{"issue":"22","key":"10.1016\/j.vaccine.2018.02.029_b0045","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2018.02.029_b0050","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 YEARS of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2018.02.029_b0055","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jpain.2004.06.001","article-title":"Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory","volume":"5","author":"Coplan","year":"2004","journal-title":"J Pain"},{"issue":"2","key":"10.1016\/j.vaccine.2018.02.029_b0060","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.vaccine.2018.02.029_b0065","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/2051013615599151","article-title":"Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective","volume":"3","author":"Johnson","year":"2015","journal-title":"Ther Adv Vaccines"},{"issue":"22","key":"10.1016\/j.vaccine.2018.02.029_b0070","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18302032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18302032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:26:51Z","timestamp":1759400811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18302032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0264410X18302032"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.029","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}